Roche Tasmar Relabeling Adds Patient Consent Form Citing Liver Toxicity
Executive Summary
The relabeling of Roche's Parkinson's therapy Tasmar (tolcapone) to reflect reports of severe liver toxicity includes a consent form requiring patients to acknowledge that they are risking fatal side effects by taking the drug.
You may also be interested in...
Novartis/Orion Comtan Enters COMT Field Without Liver Warnings
Novartis will launch Comtan into the catechol-O-methyltransferase inhibitor class without warnings concerning hepatic toxicity.
Novartis/Orion Comtan Enters COMT Field Without Liver Warnings
Novartis will launch Comtan into the catechol-O-methyltransferase inhibitor class without warnings concerning hepatic toxicity.
Roche Discussing Tasmar Reintroduction With EU Regulators
Roche is pursuing the possible European reintroduction of the Parkinson's therapy Tasmar (tolcapone) for a limited patient group through discussions with EU regulators.